Ozmosi | 177Lu]Lu-DPI-4452 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

177Lu]Lu-DPI-4452

Alternative Names: 177Lu]Lu-DPI-4452
Clinical Status: Active
Latest Update: 2025-04-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Debiopharm
Company Location: Europe
Company Founding Year: 1979
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 177Lu]Lu-DPI-4452

Countries in Clinic: Australia, France

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Bladder Cancer|Clear Cell Adenocarcinoma|Colorectal Cancer|Ductal Breast Carcinoma|Head and Neck Cancer|Muscle Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Renal Cell Carcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05706129

 Debio 0228-101

P2

Recruiting

Pancreatic Ductal Carcinoma|Bladder Cancer|Renal Cell Carcinoma|Transitional Cell Carcinoma|Squamous Cell Carcinoma|Ductal Breast Carcinoma|Muscle Cancer|Colorectal Cancer|Pancreatic Cancer|Triple Negative Breast Cancer|Head and Neck Cancer|Clear Cell Adenocarcinoma|Non-Small-Cell Lung Cancer

2027-06-01

2025-04-23

Primary Endpoints

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions